The chromosome 17q21 region is one of the most intensively studied loci in immunogenetics. A dense block of over 130 SNPs in strong linkage disequilibrium spans six genes — IKZF3, ZPBP2, GSDMB, ORMDL3, LRRC3C, and GSDMA — and has been independently associated with asthma, rheumatoid arthritis, Crohn's disease, type 1 diabetes, Graves' disease, and primary biliary cholangitis. The rs2872507 variant sits within this regulatory haploblock and influences transcription levels of ORMDL3 and GSDMB¹¹ influences transcription levels of ORMDL3 and GSDMB
rs2872507 genotype correlates strongly with ORMDL3 gene expression in airway cells; GG=highest, AA=lowest expression in a genotype-dependent manner.

IKZF3 encodes Aiolos, a zinc finger transcription factor in the Ikaros family. Aiolos is essential for B cell maturation and plasma cell differentiation²² Aiolos is essential for B cell maturation and plasma cell differentiation
Aiolos regulates B cell activation and maturation, Th17 differentiation, and NK cell maturation and plays a non-redundant role in silencing IL-2 expression in developing Th17 cells³³ silencing IL-2 expression in developing Th17 cells
Aiolos binds directly to the IL-2 promoter and triggers chromatin modifications that shut down IL-2 transcription, promoting Th17 polarization, thereby facilitating Th17 differentiation. Dysregulated Aiolos activity could shift the balance toward pathological Th17 responses that drive multiple autoimmune conditions.

The Mechanism

rs2872507 is a regulatory variant⁴⁴ regulatory variant
An intergenic/regulatory SNP that modulates the expression of neighboring genes rather than changing a protein sequence embedded in a complex regulatory landscape. The A and G alleles are associated with differential chromatin accessibility and transcription factor binding at this locus — 17q21 risk variants alter CTCF binding sites and affect IL-2 production by T cells⁵⁵ 17q21 risk variants alter CTCF binding sites and affect IL-2 production by T cells
Nature Communications 2016 study showed that 17q21 SNPs switch CTCF insulator binding and reshape the local enhancer landscape, altering long-range gene regulation across the entire haploblock.

ORMDL3 is the best-characterized effector gene at this locus. It encodes an endoplasmic reticulum transmembrane protein that regulates sphingolipid synthesis⁶⁶ sphingolipid synthesis
ORMDL3 is a key regulator of serine palmitoyltransferase, the rate-limiting enzyme in de novo sphingolipid biosynthesis and ER stress responses. Overexpression of ORMDL3 elevates ER stress markers and activates NF-κB and STAT3 signaling, promoting airway inflammation. The GG genotype drives approximately 60% higher ORMDL3 expression than AA in airway cells.

The Evidence

The landmark Moffatt et al. 2007 GWAS⁷⁷ landmark Moffatt et al. 2007 GWAS
994 childhood asthma cases vs 1,243 controls; 17q21 SNPs showed p<10⁻¹²; ORMDL3 expression correlated most strongly of all 17q21 genes established this locus as the strongest GWAS signal for childhood asthma⁸⁸ strongest GWAS signal for childhood asthma
SNPs on chromosome 17q21 were found to be strongly and reproducibly associated with childhood-onset asthma ever identified at the time. The G allele (and GG genotype) confers asthma susceptibility via elevated ORMDL3 expression.

Counterintuitively, the same locus shows the opposite effect in autoimmune diseases⁹⁹ opposite effect in autoimmune diseases
Li et al. 2012 showed rs2872507 A allele is protective for asthma but a risk allele for rheumatoid arthritis, Crohn's disease, and ulcerative colitis. A multiethnic GWAS for rheumatoid arthritis confirmed rs2872507 at genome-wide significance¹⁰¹⁰ confirmed rs2872507 at genome-wide significance
rs2872507 reached p=1.7×10⁻⁹ across 16,659 RA cases and 49,174 controls in European and East Asian populations, with the A allele as the RA risk allele. The bioinformatic analyses from that study pointed to IKZF3-ORMDL3-GSDMB as the causal gene cluster.

IKZF3 variants at this locus are also associated with Graves' disease¹¹¹¹ associated with Graves' disease
rs2872507 A allele showed OR=1.27 (p=0.004) for Graves' disease; no association found with Hashimoto's thyroiditis in 604 GD and 311 HT patients vs 814 controls, suggesting that the A allele promotes anti-thyroid autoimmunity specifically. In Chinese Han populations, different IKZF3 SNPs in the same LD block (notably rs907091) showed associations with SLE susceptibility¹²¹² associations with SLE susceptibility
rs907091 CC genotype protective against SLE (OR=0.38, p=0.001); rs2872507 itself showed no significant SLE association in this population, illustrating that the pleiotropic effects of this locus vary by both ancestry and the specific disease.

A pharmacogenomics study found that the AA genotype responds best to inhaled corticosteroids¹³¹³ AA genotype responds best to inhaled corticosteroids
AA genotype showed 13.3% FEV1 improvement vs 7.0% for AG and 4.9% for GG after ICS therapy (p=0.0176) — a finding explained by lower baseline ORMDL3 expression in AA individuals, leaving more room for corticosteroid-mediated suppression.

Practical Implications

The clinical picture for rs2872507 depends on which end of the spectrum is relevant to you. For autoimmune disease risk (RA, Crohn's, Graves' thyroiditis), the A allele — and particularly the AA genotype — confers elevated risk through IKZF3/Aiolos-mediated effects on B cell activation and Th17 regulation. For asthma, the GG genotype is the risk profile; the A allele carriers have lower ORMDL3 expression and less airway hyperreactivity. In the autoimmune-inflammation context, carriers of the A allele should be alert to early signs of inflammatory arthritis, thyroid dysfunction, and intestinal inflammation, especially when combined with other autoimmune risk variants.

Periodic monitoring of inflammatory markers (CRP, ESR) and organ-specific autoantibody panels (anti-CCP for RA, anti-TPO for thyroid disease, calprotectin for intestinal inflammation) can enable early detection of subclinical autoimmunity at the stage when intervention is most effective.

Interactions

The 17q21 locus lies in strong LD, meaning rs2872507 is in linkage with multiple other functional variants including rs8076131, rs12936231, and rs907091. The independent RA risk in this region has been confirmed across rs2872507 alongside contributions from PTPN22 (rs2476601) and HLA loci. Because IKZF3/Aiolos directly regulates Th17 cell polarization — a central pathway in RA, Crohn's disease, and psoriatic arthritis — compound risk from multiple Th17-pathway variants (e.g. IL23R, IL17A variants in other categories) may amplify the effect. The rs2476601 (PTPN22 R620W) and rs2872507 (IKZF3) combination warrants compound action consideration given independent contributions to autoimmune risk through distinct but converging pathways (T-cell tolerance vs. Th17 differentiation).

The PICALM gene¹¹ The PICALM gene
PICALM (Phosphatidylinositol binding clathrin assembly protein) orchestrates clathrin-mediated endocytosis, a cellular process critical for transporting molecules across cell membranes. Located on chromosome 11q14.2, PICALM is expressed most abundantly in brain microvessels—the endothelial cells forming the blood-brain barrier—where it plays a central role in clearing toxic amyloid-beta (Aβ) peptides from the brain. The rs3851179 variant, situated approximately 88 kb upstream of the PICALM gene, has emerged as one of the most consistently replicated genetic risk factors for late-onset Alzheimer's disease after APOE and BIN1.

The Mechanism

PICALM regulates the blood-brain barrier's ability to clear amyloid-beta from the brain into the bloodstream²² PICALM regulates the blood-brain barrier's ability to clear amyloid-beta from the brain into the bloodstream
The protein facilitates clathrin-dependent internalization of Aβ bound to LRP1 (low density lipoprotein receptor-related protein-1), a key clearance receptor, and guides the Aβ-LRP1 complex to endosomes for transcytosis—transport across the endothelial cell wall. The rs3851179 T allele, which is protective against Alzheimer's, correlates with increased PICALM expression in brain endothelium³³ The rs3851179 T allele, which is protective against Alzheimer's, correlates with increased PICALM expression in brain endothelium
In contrast, reduced PICALM expression—associated with the G allele—impairs Aβ clearance, accelerates Aβ accumulation in the brain, and correlates with cognitive impairment.

The variant is intergenic, located in a regulatory region between PICALM and the EED gene⁴⁴ The variant is intergenic, located in a regulatory region between PICALM and the EED gene
It does not change the PICALM protein sequence but appears to affect gene expression levels. PICALM is also linked functionally to ABCB1/P-glycoprotein, another Aβ clearance protein, suggesting a coordinated transcytosis system for removing brain-derived amyloid⁵⁵ PICALM is also linked functionally to ABCB1/P-glycoprotein, another Aβ clearance protein, suggesting a coordinated transcytosis system for removing brain-derived amyloid.

The Evidence

The initial discovery came from a genome-wide association study of over 5,000 Alzheimer's patients and 10,000 controls⁶⁶ The initial discovery came from a genome-wide association study of over 5,000 Alzheimer's patients and 10,000 controls
Carriers of the T allele showed a 15% reduced risk of Alzheimer's disease (OR 0.85, p=1.9×10⁻⁸). This association has been replicated across multiple ethnicities⁷⁷ This association has been replicated across multiple ethnicities
A 2016 meta-analysis of 9,435 samples confirmed the association in Chinese populations, and a 2018 systematic review of 16 case-control studies across Caucasian and Asian populations found significant associations in all genetic models examined⁸⁸ a 2018 systematic review of 16 case-control studies across Caucasian and Asian populations found significant associations in all genetic models examined.

The protective effect of the T allele remains evident even in APOE ε4 non-carriers⁹⁹ The protective effect of the T allele remains evident even in APOE ε4 non-carriers
suggesting PICALM acts through a mechanism independent of APOE. Interestingly, the T allele shows protective effects not only for Alzheimer's but also for Parkinson's disease in some populations¹⁰¹⁰ Interestingly, the T allele shows protective effects not only for Alzheimer's but also for Parkinson's disease in some populations, highlighting PICALM's broader role in neurodegeneration.

Functional studies demonstrate that the T allele is associated with increased PICALM mRNA expression in brain tissue¹¹¹¹ Functional studies demonstrate that the T allele is associated with increased PICALM mRNA expression in brain tissue
particularly in microvessels, and that this increase correlates with greater amyloid-beta clearance capacity. Mouse models with reduced Picalm expression show accelerated Aβ pathology and cognitive deficits, which can be reversed by restoring endothelial PICALM expression¹²¹² Mouse models with reduced Picalm expression show accelerated Aβ pathology and cognitive deficits, which can be reversed by restoring endothelial PICALM expression.

Practical Implications

While you cannot change your PICALM genotype, understanding your genetic risk profile can inform proactive strategies. The CC genotype confers modestly increased Alzheimer's risk, but this is just one piece of a multifactorial puzzle. Lifestyle factors—cardiovascular health, cognitive engagement, exercise, and sleep quality—significantly influence Alzheimer's risk regardless of genetics.

PICALM's role in vascular amyloid clearance underscores the importance of maintaining blood-brain barrier integrity¹³¹³ PICALM's role in vascular amyloid clearance underscores the importance of maintaining blood-brain barrier integrity
Cardiovascular risk factors (hypertension, diabetes, high cholesterol) damage the blood-brain barrier and impair its clearance function. Managing these factors may help compensate for genetic vulnerabilities in the PICALM pathway.

Interactions

The PICALM rs3851179 variant does not operate in isolation. While the protective effect of the A allele is independent of APOE ε4 status, individuals carrying both APOE ε4 and the PICALM GG genotype face compounded Alzheimer's risk through different mechanisms—APOE affects amyloid aggregation and clearance through lipoprotein pathways, while PICALM regulates transcytosis across the blood-brain barrier. Other Alzheimer's risk genes including BIN1, CLU (clusterin), and CR1 (complement receptor 1) may also interact with PICALM in the broader context of brain amyloid homeostasis. The rs3851179 variant is in high linkage disequilibrium with other PICALM-region SNPs including rs10792832, rs561655, and rs541458, all of which show genome-wide significant associations with Alzheimer's disease.

CYP2C19 is a drug-metabolizing enzyme with enormous clinical significance, particularly for the antiplatelet drug clopidogrel (Plavix). The *2 allele¹¹ rs4244285 is the most common loss-of-function variant, rendering the enzyme completely non-functional. This variant carries an FDA black-box warning²² FDA black-box warning
Clopidogrel (Plavix) prescribing label, FDA on the clopidogrel label - one of the clearest examples of pharmacogenomics directly affecting prescribing decisions.

The Mechanism

The CYP2C19*2 variant is a synonymous change (G>A at position 681 in exon 5) that creates an aberrant splice site³³ Despite being synonymous at the protein level, this variant disrupts normal mRNA splicing, producing a truncated, non-functional protein. Although the nucleotide change itself does not alter the encoded amino acid (Pro227=), it introduces a cryptic splice site that shifts the reading frame, leading to a premature stop codon. Homozygous carriers (AA) have no CYP2C19 activity and are classified as poor metabolizers.

The Clopidogrel Crisis

Clopidogrel is a prodrug⁴⁴ A prodrug is inactive until the body converts it to its active form that REQUIRES CYP2C19 to be converted to its active antiplatelet metabolite. Poor metabolizers who take clopidogrel after coronary stent placement have significantly higher rates of stent thrombosis, heart attack, and cardiovascular death. A landmark study by Mega et al.⁵⁵ landmark study by Mega et al.
Mega JL et al. Reduced-function CYP2C19 genotype and risk of cardiovascular events. JAMA, 2010 confirmed this association across multiple trials, leading to the FDA black-box warning⁶⁶ FDA black-box warning
Clopidogrel (Plavix) prescribing label, FDA.

Beyond Clopidogrel

CYP2C19 also metabolizes proton pump inhibitors (PPIs like omeprazole and pantoprazole), certain antidepressants (citalopram, escitalopram, sertraline), and antifungal agents (voriconazole). For PPIs, poor metabolizers actually benefit because the drug stays active longer, providing better acid suppression. For antidepressants, poor metabolizers may need dose reductions.

What You Should Do

If you are a poor metabolizer (AA), the clopidogrel information is potentially life-saving. If you ever need antiplatelet therapy (after a stent, stroke, or peripheral vascular disease), you MUST use an alternative like prasugrel or ticagrelor. Share this information with your cardiologist and keep it in your medical records.

The histamine H1 receptor (HRH1) sits at the front line of the allergic response. When mast cells and basophils release histamine — triggered by allergens, infections, certain foods, or stress — H1R is the molecular switch that converts that signal into the familiar cascade of sneezing, itching, swollen tissue, and bronchoconstriction. How readily and how intensely your body responds to histamine depends in part on how many H1R receptors are actually expressed on your cell surfaces.

The rs4684059 variant sits within an intron of the HRH1 gene on chromosome 3p25.3. Intronic variants in this region tag functional haplotypes that alter HRH1 transcriptional regulation¹¹ transcriptional regulation
the process by which DNA is read into RNA, controlling how much of a protein is made. The C allele is carried by roughly 36% of the global population, with frequencies reaching 43% in East Asian and European populations.

The Mechanism

The HRH1 gene contains a large 5' intron (~5.8 kb) immediately upstream of the start codon — a structural feature shared across the G-protein-coupled receptor superfamily. Variants within this region influence gene expression levels²² gene expression levels
how much HRH1 receptor protein is produced rather than changing the receptor's amino acid sequence. Lower receptor density means weaker histamine signaling per unit of histamine released; higher density means stronger, more persistent allergic responses.

A functional study of HRH1 genotypes in oral epithelial cells found that cells carrying the minor-allele genotypes of related HRH1 intronic variants expressed significantly lower HRH1 protein compared to reference-homozygote cells ³³ Ding et al. PMC9186772, 2022. This expression difference provides the biological basis for genotype-dependent variation in histamine sensitivity and antihistamine response.

The Evidence

The pharmacogenomics of HRH1 polymorphisms is an emerging research area. The best-studied HRH1 variant, rs901865 (-17C/T), tags the same gene region and has documented effects on receptor expression and antihistamine pharmacodynamics.

A case-control study in 389 Chinese Han subjects found that HRH1 -17 CC homozygotes had significantly enhanced efficacy with oral H1-antihistamines for allergic rhinitis compared to CT/TT genotype carriers, while CT and TT genotypes were overrepresented among rhinitis cases — suggesting the minor T allele both increases allergic susceptibility and reduces drug response ⁴⁴ Wang et al. PMID 30168182.

A separate study of 114 Chinese patients with chronic spontaneous urticaria found that those carrying the rs901865 G/G genotype suffered significantly more severe sedation after desloratadine treatment than G/A carriers (p=0.005), implicating HRH1 receptor levels in CNS histamine signaling as well ⁵⁵ Deng et al. PMID 31406237.

In a cohort of 202 children with asthma, the HRH1 TT genotype (minor allele homozygotes) was overrepresented among those with allergic vs nonallergic asthma, particularly in African-American children (13% vs 0%, p=0.04 in a recessive model), suggesting the minor allele haplotype tags differential allergic sensitization ⁶⁶ Anvari et al. PMID 25909280.

Note: rs4684059 itself has not been independently studied in clinical trials. The evidence above derives from functionally related HRH1 intronic variants in the same gene region that likely tag overlapping haplotypes. The evidence level is therefore emerging.

Practical Actions

For individuals carrying one or two copies of the C allele, the implication is altered HRH1 expression and potentially reduced antihistamine efficacy compared to GG homozygotes. This argues for attention to histamine trigger load (dietary and environmental) and awareness that standard antihistamine dosing may be less effective.

Quercetin, a natural flavonoid found in capers, red onions, and apples, has documented H1R antagonist activity independent of the receptor expression level and can complement antihistamine therapy. Low-histamine dietary approaches reduce the substrate load reaching the receptor regardless of receptor density.

Interactions

The HRH1 receptor pathway interacts closely with histamine-degrading enzymes. Individuals who combine low-activity AOC1/DAO (diamine oxidase) variants — which reduce histamine breakdown in the gut — with C-allele HRH1 variants face a dual burden: more histamine reaching the circulation AND potentially altered receptor sensitivity. Similarly, HNMT variants that reduce intracellular histamine methylation (the dominant CNS clearance route) interact with HRH1 receptor levels to shape neurological histamine effects including alertness and sleep onset. These interactions warrant compound actions across the histamine pathway.

The liver performs hundreds of metabolic tasks simultaneously, and one of the most consequential is converting cholesterol into bile acids — detergent-like molecules that emulsify dietary fat and carry metabolic waste out of the body. This process is tightly regulated, because too little bile acid impairs digestion and too much accumulates to toxic levels in hepatocytes. The transcription factor HNF4A (hepatocyte nuclear factor 4 alpha)¹¹ HNF4A (hepatocyte nuclear factor 4 alpha)
A nuclear receptor expressed in liver, pancreas, kidney, and intestine; controls expression of genes involved in glucose metabolism, lipid transport, bile acid synthesis, and drug metabolism sits at the center of this regulation as one of the primary transcriptional activators of the bile acid synthesis pathway.

rs6017340 is an intronic variant within the HNF4A gene on chromosome 20 that functions as a tag SNP — a marker in linkage disequilibrium with nearby functional variants that influence HNF4A expression or regulatory activity. Alone, an intronic variant does not alter protein sequence; its significance comes from what nearby variants it represents in a given haplotype block. The C allele at this position tags haplotypes that, in at least one cohort study, were associated with faster progression of a cholestatic liver disease driven by bile acid accumulation.

The Mechanism

HNF4A acts as a master transcriptional activator of CYP7A1²² CYP7A1
Cholesterol 7alpha-hydroxylase — the rate-limiting enzyme converting hepatic cholesterol to primary bile acids; accounts for ~50% of total daily cholesterol disposal in humans (cholesterol 7alpha-hydroxylase), the rate-limiting enzyme of the classic bile acid synthesis pathway. When HNF4A binds to the CYP7A1 promoter, it activates transcription and ramps up bile acid production. Experimental studies confirm that reducing HNF4A occupancy at the CYP7A1 promoter — whether through glucagon-mediated phosphorylation³³ glucagon-mediated phosphorylation
Song & Chiang 2006 — glucagon-cAMP pathway phosphorylates HNF4alpha, reducing its promoter binding and suppressing CYP7A1 transcription or through upstream transcriptional regulators — directly lowers bile acid output. Conversely, higher HNF4A activity means more CYP7A1, more bile acid synthesis, and higher hepatic bile acid flux.

Haplotypes tagged by the C allele at rs6017340 are proposed to influence this regulatory equilibrium. If C-tagging haplotypes are associated with elevated HNF4A activity in liver tissue, the result would be greater CYP7A1-driven bile acid production. In individuals with intact bile acid clearance, this excess is excreted harmlessly. But in patients with cholestatic conditions — where bile cannot be efficiently cleared — higher bile acid synthesis rates translate directly into greater hepatocyte accumulation and accelerated liver injury.

The Evidence

The sole direct association study for rs6017340 is Inamine et al. 2013⁴⁴ Inamine et al. 2013
Inamine T et al. Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol, 2013, which analyzed 52 tag SNPs across 11 bile acid synthesis genes in 315 Japanese patients with primary biliary cholangitis (PBC). Two HNF4A tag SNPs — rs6017340 and rs6031587 — showed significant association with disease progression. The proposed mechanism is that genetic variants activating HNF4A's role in CYP7A1 transcription elevate bile acid synthesis, worsening hepatocyte bile acid accumulation in the context of impaired biliary excretion.

This is a small, single-cohort study in an ethnically specific population, and the rsid does not appear in the GWAS Catalog and carries no ClinVar annotation. The evidence is classified as emerging — the biological mechanism is well-supported by independent literature, but the specific genetic association has not been replicated in larger studies. It is possible that rs6017340 is tagging a different causal variant that shows stronger association in Japanese populations (where the C allele reaches ~82% frequency vs ~45% in Europeans).

In the broader HNF4A context, the gene is well-established as a susceptibility locus for MODY1 (maturity-onset diabetes of the young type 1)⁵⁵ MODY1 (maturity-onset diabetes of the young type 1)
An autosomal dominant form of monogenic diabetes caused by loss-of-function HNF4A mutations; presents typically before age 25, initially responsive to sulfonylureas through rare coding mutations, and population-level HNF4A haplotypes have been associated with type 2 diabetes risk, insulin secretion, and hepatic lipid metabolism in GWAS. The rs6017340 variant is specifically associated with bile acid synthesis regulation rather than glucose homeostasis, representing a distinct functional arm of HNF4A's broad hepatic regulatory role.

Practical Implications

For carriers of the C allele, the actionable implications are confined to liver health monitoring rather than active dietary intervention. The emerging evidence links this variant specifically to progression risk in cholestatic liver disease — a condition where bile flow is impaired — rather than to general metabolic risk. Most C allele carriers will never develop PBC, which affects roughly 1 in 1,000 women (with a strong female predominance) and has a complex multifactorial etiology requiring both genetic predisposition and environmental or immunological triggers.

The most clinically useful response to the C allele is awareness of cholestatic liver disease symptoms — persistent itching (pruritus), fatigue, and right upper quadrant discomfort — and appropriate use of standard liver function testing. Ursodeoxycholic acid (UDCA), which competitively replaces more toxic bile acids and reduces CYP7A1 expression via FXR activation, is the established treatment for PBC and directly addresses the bile acid overproduction mechanism implicated by this variant.

Interactions

Within HNF4A, rs6017340 acts as a haplotype tag alongside rs6031587, and both variants were identified together in the PBC progression study. Compound heterozygosity or homozygosity at the full haplotype block likely produces stronger effects than either tag SNP captures individually.

Pathway partners include CYP7A1 variants (rs3808607 and rs3824260), which directly alter CYP7A1 promoter activity and interact with HNF4A-driven transcription. Individuals carrying both HNF4A C-tagging haplotypes and CYP7A1 promoter risk alleles may face additive upregulation of bile acid synthesis through both the transcription factor and the target gene. PPARGC1A variants were also co-identified in the same bile acid synthesis study, as PPARGC1A is an HNF4A coactivator that amplifies transcriptional output.

The CYP19A1 gene encodes aromatase, the enzyme responsible for converting androgens into estrogens in the final step of estrogen biosynthesis. Located on chromosome 15q21.1¹¹ Located on chromosome 15q21.1
The gene spans approximately 123 kb with complex tissue-specific regulation, aromatase is expressed in gonads, adipose tissue, bone, breast, and brain. The rs700518 variant is a synonymous G>A substitution at codon 80 (Val80Val) in exon 3. While it doesn't change the amino acid sequence, this variant affects post-transcriptional gene regulation, leading to differences in aromatase expression and activity²² this variant affects post-transcriptional gene regulation, leading to differences in aromatase expression and activity.

The Mechanism

Though synonymous, rs700518 influences aromatase enzyme levels through effects on mRNA stability, translation efficiency, or linkage with regulatory variants. The CC genotype has been associated with higher aromatase expression in some tissues³³ The CC genotype has been associated with higher aromatase expression in some tissues, while the TT genotype appears to result in lower enzyme activity. This translates to differences in the conversion of testosterone to estradiol and androstenedione to estrone. Studies in women with hyperandrogenism found the CC genotype associated with lower estradiol levels and higher SHBG concentrations⁴⁴ Studies in women with hyperandrogenism found the CC genotype associated with lower estradiol levels and higher SHBG concentrations, suggesting tissue- and context-specific effects.

The variant is closely linked (high linkage disequilibrium) with rs10046 in the 3'-UTR region⁵⁵ rs10046 in the 3'-UTR region, and together these SNPs form haplotypes that influence aromatase activity across multiple tissues. This explains why effects can be complex and sometimes appear contradictory — the functional impact depends on which other variants are present and the tissue context.

The Evidence

The strongest evidence for rs700518 comes from studies of aromatase inhibitor therapy in breast cancer. A prospective study of 97 postmenopausal women found that those with the TT genotype developed significant bone loss at the lumbar spine and hip after 12 months of AI therapy⁶⁶ A prospective study of 97 postmenopausal women found that those with the TT genotype developed significant bone loss at the lumbar spine and hip after 12 months of AI therapy
Napoli N et al. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER (+) breast cancer. Bone. 2013 (both p=0.03), while those carrying a C allele maintained bone density. In the same cohort, women with the CC genotype showed opposite body composition changes — significant increases in truncal fat and decreases in lean mass⁷⁷ women with the CC genotype showed opposite body composition changes — significant increases in truncal fat and decreases in lean mass.

A meta-analysis of 8 studies involving 2,632 subjects confirmed that the TC genotype is associated with significantly lower bone mineral density at both lumbar spine and femoral neck⁸⁸ A meta-analysis of 8 studies involving 2,632 subjects confirmed that the TC genotype is associated with significantly lower bone mineral density at both lumbar spine and femoral neck (p=0.001 and p=0.01, respectively). The relationship with osteoporosis risk was less clear, but the consistent BMD findings suggest bone health implications.

Beyond breast cancer treatment, a study of Chinese women found the TT genotype conferred a 3.66-fold increased risk of endometriosis-related infertility⁹⁹ a study of Chinese women found the TT genotype conferred a 3.66-fold increased risk of endometriosis-related infertility (OR 3.66, 95% CI 2.06-6.50, p<0.001) compared to controls. This was specific to infertility, not endometriosis alone. Research in women with hyperandrogenism showed the CC genotype associated with lower estradiol levels and altered fat distribution patterns¹⁰¹⁰ Research in women with hyperandrogenism showed the CC genotype associated with lower estradiol levels and altered fat distribution patterns, demonstrating effects beyond cancer treatment contexts.

Practical Implications

For women taking aromatase inhibitors for breast cancer, this variant predicts side effect risk. The TT genotype indicates higher risk of accelerated bone loss, while the CC genotype predicts unfavorable body composition changes. Both warrant closer monitoring, though the interventions differ. For general population health, the variant influences baseline estrogen levels, which affect bone density, body composition, cardiovascular risk, and reproductive health across the lifespan.

The evidence supports bone density monitoring and proactive bone health interventions for T allele carriers, particularly women approaching or past menopause. The CC genotype's association with altered body composition suggests attention to lean mass preservation through resistance exercise and adequate protein intake may be especially important.

Interactions

Rs700518 is part of a haplotype block with rs10046 and rs4646, both in the 3'-untranslated region of CYP19A1. These variants show high linkage disequilibrium and their combined effects may be stronger than any single SNP. Other CYP19A1 variants including rs749292, rs1062033, and rs4775936 also influence aromatase activity and may interact to determine overall enzyme function.

Interactions with estrogen receptor variants (ESR1, ESR2) likely modulate the clinical impact of altered estrogen production. In women taking aromatase inhibitors, the degree of estrogen suppression achieved depends on both baseline aromatase activity (influenced by this variant) and how well the drug inhibits the enzyme, creating pharmacogenetic interactions that affect both efficacy and toxicity.

The FADS2 gene encodes delta-6 desaturase¹¹ delta-6 desaturase
The enzyme responsible for the first rate-limiting step in converting dietary short-chain polyunsaturated fats into their biologically active long-chain forms — adding a double bond at the 6-position of the fatty acid chain, the enzyme that performs the first critical step in converting the essential fats you eat — linoleic acid (omega-6) from vegetable oils and alpha-linolenic acid (omega-3) from flaxseed and walnuts — into longer, more biologically active forms such as arachidonic acid (ARA), eicosapentaenoic acid (EPA), and ultimately docosahexaenoic acid (DHA). The rs99780 variant is an intronic single nucleotide polymorphism within the FADS1-FADS2 gene cluster²² FADS1-FADS2 gene cluster
A highly conserved genomic region on chromosome 11q12.2 containing FADS1, FADS2, and FADS3 in tandem — the most replicated GWAS locus for circulating fatty acid levels in humans on chromosome 11, a region consistently identified as the dominant genetic determinant of circulating polyunsaturated fatty acid (PUFA) composition across populations.

The Mechanism

rs99780 does not alter the FADS2 protein sequence — it is located within an intron. However, as part of the haplotype structure of the FADS cluster, it tags a regulatory state that influences FADS2 expression and delta-6 desaturase activity³³ FADS2 expression and delta-6 desaturase activity
Intronic and regulatory variants in the FADS cluster are thought to influence transcription factor binding and local chromatin state, modulating the amount of FADS2 enzyme produced rather than its structure or kinetics. The T allele at rs99780 co-segregates with minor alleles at neighboring FADS variants (rs174553, rs174575, rs174583) to form a haplotype associated with reduced FADS2 activity. The consequence of reduced delta-6 desaturase activity is a systemic shift in PUFA metabolism:

• Omega-6 pathway: Less linoleic acid (LA) is converted to gamma-linolenic acid (GLA) and then to arachidonic acid (ARA), the major omega-6 long-chain PUFA
• Omega-3 pathway: Less alpha-linolenic acid (ALA) is converted to stearidonic acid (SDA) and then toward EPA — reducing endogenous EPA synthesis from plant-based omega-3 sources

The net result is accumulation of precursor fatty acids (LA, ALA) and depletion of long-chain products (ARA, EPA), a pattern directly measurable in blood and tissue phospholipids.

The Evidence

The foundational evidence for rs99780 specifically comes from a study by Xie and Innis⁴⁴ Xie and Innis
Xie L, Innis SM. Genetic variants of the FADS1 FADS2 gene cluster are associated with altered (n-6) and (n-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. J Nutr, 2008 in 69 pregnant Canadian women. The study directly genotyped rs99780 among four FADS cluster variants. Women homozygous for the minor alleles at rs99780 showed lower ARA but higher LA in plasma phospholipids and erythrocyte ethanolamine phospholipids at 16 and 36 weeks of gestation, alongside decreased product-to-precursor ratios for both omega-6 (ARA/LA) and omega-3 (EPA/ALA) pathways. In breast milk, TT homozygotes showed significantly lower ARA and EPA — indicating that the conversion impairment persists through lactation and affects the fatty acid composition of milk provided to infants.

The broader context for this locus is established by Tanaka and colleagues⁵⁵ Tanaka and colleagues
Tanaka T et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet, 2009 in 1,075 InCHIANTI participants — the landmark GWAS demonstrating that the FADS chromosome 11 locus explains a remarkable 18.6% of additive variance in arachidonic acid levels, with genome-wide significant associations extending across multiple PUFA species. The same cluster harboring rs99780 was the top hit for EPA levels and several related fatty acids, confirming this region's central role in PUFA metabolism.

A key clinical dimension emerged from childhood cohort data: Talaei and colleagues⁶⁶ Talaei and colleagues
Talaei M et al. Intake of n-3 polyunsaturated fatty acids in childhood, FADS genotype and incident asthma. Eur Respir J, 2021 examined 4,543 children from the AVON Longitudinal Study and found that among minor allele carriers at a linked FADS2 variant (rs1535, in LD with rs99780), higher EPA+DHA intake in childhood was associated with a 51% reduction in asthma risk (OR 0.49, 95%CI 0.31–0.79; p-interaction = 0.006). Among major allele homozygotes — who can efficiently synthesize their own long-chain omega-3 from plant ALA — no protective effect was found (OR 1.43), suggesting that supplemental EPA/DHA specifically benefits those who cannot make it endogenously.

A review of the evidence by O'Neill and Minihane⁷⁷ O'Neill and Minihane
O'Neill CM, Minihane AM. The impact of fatty acid desaturase genotype on fatty acid status and cardiovascular health in adults. Proc Nutr Soc, 2017 confirmed the consistent pattern: FADS minor allele carriers have higher plasma and tissue concentrations of LA and ALA (precursors), lower ARA, lower EPA, and somewhat lower DHA. Critically, dietary total fat and fatty acid composition modifies these relationships — indicating that diet can amplify or attenuate the genetic effect.

Practical Actions

The core implication is straightforward: people carrying the T allele at rs99780 have a genetically limited capacity to convert plant-based omega-3 and omega-6 fatty acids into their long-chain active forms. This makes preformed EPA and DHA from marine sources or algae supplements more important than for people with full FADS2 activity. Plant-based omega-3 sources (flaxseed, chia, walnuts) supply only ALA, which requires the impaired FADS2 → delta-6 desaturase step to reach EPA. Relying on these sources as the primary omega-3 strategy is insufficient for T allele carriers.

The gene-nutrient interaction data also suggest that EPA/DHA supplementation may provide health benefits in T allele carriers that do not apply equally to CC homozygotes — including potential protection against atopic conditions and inflammatory outcomes.

Interactions

rs99780 is part of the FADS1-FADS2 haplotype block that includes rs174537 and rs174547 (both already in the GeneOps platform). These variants are in partial linkage disequilibrium (LD) and may produce additive effects when co-inherited. rs174537 (FADS1, in the triglycerides-fatty-acids category) specifically affects delta-5 desaturase activity — the downstream step converting DGLA to ARA and ETA to EPA. Carrying impaired alleles at both FADS2 (rs99780) and FADS1 (rs174537/rs174547) compounds the disruption across the full PUFA elongation cascade, potentially creating a more severe functional omega-3/omega-6 deficiency than either variant alone.

rs174575 (FADS2) and rs1535 (FADS2) are additional SNPs in the cluster not yet in the platform that may provide further resolution on FADS2 activity.

Deep in the airways, a molecular balancing act governs whether bronchial smooth muscle stays relaxed or tightens toward an asthma attack. One of the key players is ADH5 — formally S-nitrosoglutathione reductase (GSNOR) — an enzyme that degrades S-nitrosoglutathione (GSNO)¹¹ S-nitrosoglutathione (GSNO)
GSNO is the predominant bioactive form of nitric oxide in airway lining fluid; it relaxes smooth muscle at nanomolar concentrations, roughly 100 times more potently than the asthma drug theophylline, the lung's primary endogenous bronchodilator. rs28730619 sits within an intron of the ADH5 gene on chromosome 4 and tags a haplotype associated with elevated GSNOR activity and childhood asthma risk.

The Mechanism

GSNOR catalyses the NADH-dependent conversion of GSNO to oxidized glutathione and ammonia, irreversibly removing GSNO from airway lining fluid. When GSNOR activity is elevated, S-nitrosothiol (SNO) levels fall²² S-nitrosothiol (SNO) levels fall
SNOs include GSNO and protein-bound nitrosothiols; they are potent bronchodilators depleted in asthmatic lungs, smooth muscle tone rises, and airway hyperresponsiveness follows. The enzyme also detoxifies formaldehyde (via the spontaneous glutathione adduct S-hydroxymethylglutathione), providing a secondary role in airway protection from irritants.

rs28730619 is an intronic variant and does not alter the GSNOR protein directly. Its asthma association most likely reflects linkage disequilibrium³³ linkage disequilibrium
LD means this SNP travels with nearby functional variants across generations; the C allele at rs28730619 marks a chromosomal haplotype rather than being directly causal with functional variants elsewhere in the gene. A closely related promoter SNP, rs1154404, shows near-complete LD with rs28730619 in some haplotypes and has been proposed to disrupt an NF-κB binding site, potentially increasing baseline GSNOR transcription. Other ADH5 promoter variants (rs2602899, rs2851301) at suspected NF-κB sites are associated with decreased asthma risk through reduced GSNOR expression — the inverse of what rs28730619 tags — reinforcing the idea that GSNOR expression level, rather than protein function, is the key modifiable variable.

The Evidence

The primary association study enrolled 532 nuclear families⁴⁴ 532 nuclear families
Case-parent triad design: each triad comprises one asthmatic child and both biological parents; family-based association testing controls for population stratification artifacts with asthmatic children aged 4–17 years in Mexico City. Children homozygous for the minor (C/plus-strand) allele at rs28730619 had a relative risk of 1.60 (95% CI 1.13–2.26, P = 0.0077) for asthma. The heterozygous genotype showed a trend toward increased risk (RR 1.20, 95% CI 0.92–1.55) but did not reach significance, suggesting a broadly additive or recessive dose-response pattern. The most common haplotype containing this minor C allele also conferred elevated asthma risk (RR 1.57, 95% CI 1.08–2.27, P = 0.017) in haplotype analysis.

Functional data from human bronchoalveolar lavage Que et al. 2009⁵⁵ Que et al. 2009
GSNOR activity measured in lavage fluid from 13 asthmatic and 11 healthy adults; activity correlated inversely with PC20 methacholine threshold (airway hyperresponsiveness) confirms the mechanism: GSNOR activity was twice as high in asthmatics (1,223 vs 537 AU/mg protein, p = 0.03), and total SNO levels were halved (11.2 vs 23.1 pmol/ml, p = 0.01). This aligns with mouse knockout data — ADH5-null mice are protected from allergen-induced airway hyperresponsiveness and maintain higher tissue RSNO levels.

A 2017 review Barnett & Buxton⁶⁶ Barnett & Buxton
Critical Reviews in Biochemistry and Molecular Biology; covers all human diseases where GSNOR dysregulation has been implicated notes that GSNOR inhibitors (N6022, N91115) have entered clinical trials for asthma and cystic fibrosis, underscoring the therapeutic tractability of the enzyme as a target — and, by extension, the clinical significance of genetic variants that mimic its overactivity.

The limitation of current evidence is that the genetic association derives from a single study in a Latin American pediatric cohort. Replication in European or East Asian populations is lacking, keeping the evidence level at moderate despite the strong functional plausibility.

Practical Actions

The rs28730619 C/C genotype is found in roughly 3% of the global population (higher in African and Latino populations at ~10% and ~7% respectively). For CC carriers, the practical priority is minimising triggers that further stress the GSNOR-GSNO axis and maximising endogenous nitric oxide availability in the airways.

Formaldehyde exposure — from new furniture, building materials, and cigarette smoke — is directly relevant: GSNOR is the primary enzyme that clears the formaldehyde-glutathione adduct, and high environmental formaldehyde load competes for enzyme capacity, potentially worsening the GSNO deficit. Low-nitrate vegetable intake can limit substrate for airway NO synthesis; nitrate-rich foods (beetroot, leafy greens, celery) provide dietary nitrate that the inorganic nitrate → nitrite → NO pathway can convert to NO independently of eNOS, partially bypassing the GSNOR-mediated GSNO depletion.

Interactions

rs1154404 (also in ADH5) forms part of the same haplotype as rs28730619 and is the more likely functional driver of the NF-κB–mediated transcription change. Carrying risk alleles at both SNPs compounds the signal. The beta-2 adrenergic receptor variant rs1042713 (ADRB2 Arg16Gly) interacts with GSNOR haplotypes in bronchodilator responsiveness to albuterol in Hispanic children — GSNOR and ADRB2 genotypes together predict ~70% of non-response to albuterol therapy, suggesting a compound action between these two pathways.

The brain's immune cells — microglia¹¹ microglia
Resident macrophage-like cells of the central nervous system; account for roughly 10–15% of all brain cells and are the primary defence against pathogens and cellular debris — are responsible for patrolling the brain and clearing misfolded protein aggregates, including amyloid-beta (Aβ) plaques. How well they do this job depends in part on the proteins on their surface. CD33 (also known as Siglec-3) is one such surface receptor: it acts as an inhibitory brake on phagocytic activity. When CD33 levels are high, microglia engulf less amyloid-beta. When CD33 is reduced or absent, clearance improves dramatically. rs3865444 sits 372 base pairs upstream of CD33's first exon and, through tight linkage with a functional exon 2 splice variant, is one of the most replicated genetic controls of this brake.

The Mechanism

rs3865444 is in near-perfect linkage disequilibrium with rs12459419, a variant at the fourth base of CD33 exon 2. The rs12459419 T allele (coinherited with rs3865444 A) promotes skipping of exon 2 during mRNA splicing²² The rs12459419 T allele (coinherited with rs3865444 A) promotes skipping of exon 2 during mRNA splicing
Minigene experiments in BV2 microglial cells showed the T minigene produced 10.3% exon-2-skipped transcripts versus only 3.4% for the C minigene (p = 0.034). Exon 2 encodes the immunoglobulin variable domain — the sialic acid-binding site that enables CD33 to suppress phagocytosis. A CD33 protein lacking exon 2 (D2-CD33) is functionally inert as an inhibitory receptor.

Each copy of the protective A allele at rs3865444 increases the proportion of D2-CD33 by roughly 11% and reduces total full-length CD33 protein by approximately 23% per allele, with AA homozygotes showing ~46% lower full-length CD33 than CC homozygotes³³ AA homozygotes showing ~46% lower full-length CD33 than CC homozygotes
Adjusted R² = 0.76 for the expression model; rs3865444 genotype p = 0.012. The functional consequence is unambiguous: human microglia lacking CD33 phagocytize significantly greater amounts of Aβ42 than CD33-expressing microglia⁴⁴ human microglia lacking CD33 phagocytize significantly greater amounts of Aβ42 than CD33-expressing microglia
Microglia were transfected with CD33-targeting siRNA; knockdown cells showed ~50% increase in Aβ42 uptake versus controls. In transgenic APP/PS1 mice, complete CD33 knockout reduced cortical plaque burden by 37.2% (p < 0.01) and hippocampal plaque by 33.5% (p < 0.05).

The Evidence

Two parallel GWAS consortia published genome-wide significant findings for rs3865444 in 2011. Hollingworth et al.⁵⁵ Hollingworth et al.
Combined four GWASs plus replication across stages 2–3; meta P = 1.6×10⁻⁹ for CD33 rs3865444 and Naj et al.⁶⁶ Naj et al.
Three-stage design with Alzheimer Disease Genetics Consortium data; P = 1.6×10⁻⁹ across all stages combined both independently identified CD33 as a late-onset AD susceptibility locus — a striking concordance. These remain among the most robustly replicated non-APOE loci for AD.

A meta-analysis of 18 case-control studies⁷⁷ meta-analysis of 18 case-control studies
50,030 cases and 77,405 controls; largest synthesis of rs3865444 data to date confirmed the protective A allele confers OR 0.93 (95% CI 0.90–0.97) overall. Genotype-specific analyses from independent studies show a dose-dependent effect: each copy of the A allele confers approximately 13–18% relative risk reduction (CA OR ≈ 0.87, AA OR ≈ 0.82 vs CC). The effect is most robust in European and North American populations; evidence in East Asian cohorts is weaker and heterogeneous, possibly reflecting lower A allele frequency (~19% in Korean populations versus ~34% in Europeans) or population-specific LD patterns.

Neuropathological confirmation⁸⁸ Neuropathological confirmation
Arizona Study of Aging; 193 brain-bank donors stratified by rs3865444 genotype shows AA carriers have significantly lower CD33 protein in cortex, fewer CD33-positive microglia, and lower insoluble Aβ42 levels than CC carriers, providing direct biological validation in human brain tissue.

Practical Actions

CD33 rs3865444 is a modest but mechanistically compelling AD risk modifier. Its effect is substantially smaller than APOE ε4 (which multiplies AD risk 3-fold per allele) but among the strongest non-APOE GWAS signals. CC homozygotes carry the highest CD33 expression and weakest microglial amyloid clearance from this locus. Protective strategies that support microglial function and reduce amyloid burden — particularly those with independent clinical evidence — are especially relevant for CC carriers.

Emerging therapeutic interest focuses directly on this pathway: CD33-blocking antibodies and CD33 gene-editing approaches are in preclinical development for AD, following the same logic that reducing CD33 activity improves microglial phagocytosis.

Interactions

The strongest documented interaction is with APOE ε4 (rs429358 / rs7412). APOE ε4 impairs microglial lipid metabolism and amyloid clearance through a partially distinct mechanism from CD33 inhibition; individuals carrying both CC at rs3865444 and one or more ε4 alleles face compounding microglial dysfunction. The CD33 effect appears largely additive on top of APOE ε4 risk rather than synergistic, but CC + ε4 carriers represent a high-priority group for AD risk management.

A second layer of interaction involves TREM2 (rs75932628) — another microglial receptor whose R47H variant impairs phagocytosis through a different surface receptor pathway. Individuals homozygous CC at rs3865444 and heterozygous R47H at TREM2 would have parallel deficits in two independent microglial clearance pathways.

CYP3A4 is the single most important enzyme for drug metabolism in the human body. Sitting at the gateway between the gut and the bloodstream — in the intestinal wall and liver — it processes approximately 30–50% of all clinically prescribed medications¹¹ approximately 30–50% of all clinically prescribed medications
CYP3A4 and CYP3A5 together account for the majority of CYP3A-mediated metabolism. CYP3A4 predominates in the intestine and liver; CYP3A5 is more variable across tissues and populations. Immunosuppressants given after organ transplantation, opioid analgesics, benzodiazepines, many statins, antifungals, and calcium channel blockers all depend on CYP3A4 to determine how much drug reaches — and lingers in — the body after each dose.

rs4646438 defines the CYP3A4*6 allele²² CYP3A4*6 allele
Named according to the CYP Allele Nomenclature Committee convention; *1 is wild-type and higher numbers designate variant alleles identified in order of discovery, a frameshift insertion in exon 9 that destroys the enzyme entirely. This is not a subtle reduction in efficiency: in multiple independent in vitro experiments, the *6 protein produces zero detectable catalytic activity. Any CYP3A4 substrate that enters the body of a *6 carrier has one fewer working copy of the enzyme available to clear it.

The Mechanism

The CYP3A4 gene sits on the minus strand of chromosome 7 at position 99,766,412 (GRCh38)³³ minus strand of chromosome 7 at position 99,766,412 (GRCh38)
The gene runs in the reverse direction on the chromosome — the coding strand is the minus strand, so variants described in genomic coordinates use the complementary plus-strand alleles. CYP3A4*6 is caused by an adenine insertion at coding position 17776 within exon 9, described in plus-strand (genomic) terms as a T>TT tandem duplication at GRCh38 chr7:99,766,412.

This single extra nucleotide shifts the reading frame at codon 277 (p.Asp277fs). Every codon downstream of the insertion is scrambled — the ribosome reads a completely different amino acid sequence until it encounters a premature stop codon⁴⁴ premature stop codon
An in-frame stop codon generated by the shifted reading frame, causing the ribosome to halt translation early and produce a truncated protein that terminates the protein well before its 503-amino-acid full length. The mature CYP3A4 active site — including the heme-binding Cys-pocket and the substrate-access channel — lies downstream of position 277 and is missing entirely from the truncated *6 protein.

The result is a null allele. Lee and Goldstein (2005)⁵⁵ Lee and Goldstein (2005)
Lee SJ, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 2005;6(4):357-371 classified CYP3A4*6 as a "minimal function" allele — a status it shares only with CYP3A4*17 among the known CYP3A4 variants. This is distinct from the more common CYP3A4*22 (rs35599367), which reduces expression by ~50% through a splicing defect but leaves some enzyme present.

The Evidence

The original characterization by Hsieh et al. (2001)⁶⁶ Hsieh et al. (2001)
Hsieh KP, Lin YY, Cheng CL et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001;29(3):268-273 sequenced CYP3A4 in 102 Chinese subjects and found the 17776insA allele heterozygously in one individual. Urinary 6β-hydroxycortisol-to-cortisol ratios — a well-validated phenotypic probe for in vivo CYP3A4 activity — were consistent with reduced enzyme function. The gene frequency in this initial sample was approximately 0.5%.

Subsequent in vitro functional studies have consistently confirmed complete loss of function. Cai et al. (2021)⁷⁷ Cai et al. (2021)
Cai Y, Lin Q, Jin Z et al. Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro. Chem Res Toxicol 2021;34(1):127-134 expressed 30 CYP3A4 variants as recombinant proteins and measured metabolism of oxycodone to noroxycodone by mass spectrometry. CYP3A4*6 showed no detectable enzyme activity — zero formation of the measured metabolite — placing it in the null category alongside five other alleles. In a parallel study by Han et al. (2021)⁸⁸ Han et al. (2021)
Han M, Qian J, Ye Z et al. Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro. Chem Biol Interact 2021;341:109464, CYP3A4*6 again completely lost catalytic function against the substrate acalabrutinib. A study by Lin et al. (2019)⁹⁹ Lin et al. (2019)
Lin QM, Li YH, Liu Q et al. Functional characteristics of CYP3A4 allelic variants on the metabolism of loperamide in vitro. Infect Drug Resist 2019;12:2985-2994 of 29 alleles against loperamide found that CYP3A4*6 displayed "extremely low activity or no activity" — the harshest category of impairment.

Population data from gnomAD¹⁰¹⁰ gnomAD
Genome Aggregation Database — aggregates exome and genome sequences from hundreds of thousands of individuals worldwide to estimate allele frequencies show that the *6 allele is globally rare, with an overall allele frequency of approximately 8.6×10⁻⁵ in gnomAD exomes. Notably, East Asian populations carry this allele at higher frequencies (~0.3% from ALFA East Asian data) compared to Europeans (~0.003%). The allele was identified in a Chinese cohort and appears to have originated in East Asian ancestry populations. Homozygous *6/*6 individuals would be extraordinarily rare.

Practical Actions

Because CYP3A4*6 is a null allele, not a partial reducer, its clinical implications are qualitatively different from the more common CYP3A4 variants. A heterozygous *6 carrier has one completely non-functional CYP3A4 allele and one normal allele — total functional CYP3A4 enzyme capacity is roughly halved at a molecular level. The degree of clinical impact depends on whether the wild-type allele alone can maintain adequate clearance, the co-presence of other CYP3A4-reducing variants, and any inhibitors in the environment.

For drugs with narrow therapeutic windows — tacrolimus and cyclosporine after organ transplantation, opioids for pain management, many antifungals — even a 50% reduction in CYP3A4 activity can produce dangerously elevated blood levels at standard doses. Transplant clinicians should note that CYP3A4*6 carriers require lower tacrolimus doses than extensive metabolizers and that therapeutic drug monitoring targets are especially important to establish early. For statins metabolized by CYP3A4 (simvastatin, lovastatin, atorvastatin), higher plasma levels increase myopathy risk; CYP3A4-independent statins (rosuvastatin, pravastatin) avoid this issue.

There are currently no CPIC or DPWG guidelines specific to CYP3A4*6, because the allele is too rare to power prospective clinical trials. Clinical management relies on standard therapeutic drug monitoring for narrow-therapeutic-index CYP3A4 substrates, combined with awareness that CYP3A4*6 carrier status predicts higher drug exposure than average.

Interactions

CYP3A4*6 interacts multiplicatively with other CYP3A-reducing variants. The most clinically important interaction is with CYP3A5*3 (rs776746) — the most common non-expressor allele of CYP3A5, present in ~85% of Europeans. CYP3A5 partially compensates for reduced CYP3A4 in tissues where it is expressed; a carrier who is also CYP3A5*3/*3 (no functional CYP3A5) has minimal combined CYP3A activity and belongs in the poor metabolizer tier functionally. Similarly, a *6 carrier who also carries CYP3A4*22 (rs35599367) on the other allele — one non-functional allele plus one ~50%-reduced allele — would have predicted overall CYP3A4 activity well below the intermediate range.

Environmental inhibitors (grapefruit juice, clarithromycin, ketoconazole, ritonavir) can reduce residual CYP3A4 activity by 3- to 8-fold. In a *6 heterozygote who already has one null allele, adding a strong CYP3A4 inhibitor can bring total clearance close to zero — raising drug exposure to dangerous levels particularly for tacrolimus, opioids, and benzodiazepines.